Evident™ Ovarian Cancer Screening Test

About Mercy BioAnalytics

Mercy BioAnalytics is a private, pre-revenue diagnostics company pioneering an extracellular vesicle (EV)-based liquid biopsy platform for multi-cancer early detection. Its patented Mercy Halo™ technology uses low-cost qPCR to detect co-localized biomarkers on individual EVs, aiming for high sensitivity and specificity in identifying early-stage cancers. Led by an experienced team with diagnostics industry veterans, including Chairman Stan Lapidus (founder of Exact Sciences), the company is advancing its pipeline, starting with an ovarian cancer screening test, and has established a Medicare coverage pathway strategy. Mercy positions its EV approach as a potentially superior alternative to cell-free DNA (cfDNA) methods for detecting poorly vascularized, early-stage tumors.

Therapeutic Areas